Gene expression profiling

Agendia Presents Data at Miami Breast 2024 Demonstrating MammaPrint® + BluePrint®’s Ability to Further Stratify Tumor Categories in Hormone-Positive Breast Cancer, Highlighting Response to Different Chemotherapy Regimens

Retrieved on: 
Friday, March 8, 2024

The first poster, titled MammaPrint® and BluePrint® predict anthracycline chemosensitivity in patients with HR+HER2-early-stage breast cancer enrolled in FLEX, (Audeh, W., et al.

Key Points: 
  • The first poster, titled MammaPrint® and BluePrint® predict anthracycline chemosensitivity in patients with HR+HER2-early-stage breast cancer enrolled in FLEX, (Audeh, W., et al.
  • ), investigates the associations between MammaPrint and BluePrint classifications, therapy regimen, and the likelihood of achieving a pathologic Complete Response (pCR).
  • The second poster, titled Prediction of chemotherapy benefit by MammaPrint® in patients with HR+HER2-early-stage breast cancer from real-world evidence studies (Audeh, W., et al.
  • Taken together, these findings indicate the utility of MammaPrint to predict neoadjuvant and adjuvant chemotherapy benefit in this patient population.

Asep Medical's Sepsis Diagnostic Technology Can Provide Improved Odds for Pediatric Appendicitis

Retrieved on: 
Tuesday, February 27, 2024

VANCOUVER, BC, Feb. 27, 2024 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that its proprietary gene expression signature for sepsis can provide an improved assessment of the severity of appendicitis in children.

Key Points: 
  • VANCOUVER, BC, Feb. 27, 2024 /PRNewswire/ - Asep Medical Holdings Inc. ("Asep Inc." or the "Company") (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that its proprietary gene expression signature for sepsis can provide an improved assessment of the severity of appendicitis in children.
  • The study found that the "diagnostic study of 71 patients with pediatric appendicitis using systems immunology methods revealed a mechanistic understanding of severe disease, indicating immune dysregulation similar to that observed in sepsis.
  • The study concluded that early diagnostics and management strategies for pediatric PA should be informed by underlying immune dysregulation and similarities to sepsis.
  • Based on the new potential benefits of this ER technology, we look forward to improving outcomes for children presenting with abdominal pain in the ER."

Vizgen Kicks Off AGBT with Enhanced MERFISH Chemistry Updates and 2024 Product Roadmap Highlights

Retrieved on: 
Monday, February 5, 2024

Vizgen , Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has unveiled enhanced MERFISH chemistry along with its 2024 product roadmap.

Key Points: 
  • Vizgen , Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has unveiled enhanced MERFISH chemistry along with its 2024 product roadmap.
  • In addition to the announcement of these product developments, Vizgen will be presenting three posters at the Advances in Genome Biology and Technology (AGBT) 2024 General Meeting, in Orlando, Florida, this week.
  • The enhanced MERFISH chemistry will extend the best-in-class sensitivity of MERFISH to degraded RNA samples, including archival FFPE samples, enabling translational research.
  • Data demonstrating this superior detection capacity is expected to be released in the coming months, with plans to make the enhanced MERFISH chemistry available to users in the summer of 2024.

Agendia Announces First Patient Enrolled in DEBRA Trial Using MammaPrint®

Retrieved on: 
Thursday, February 1, 2024

Agendia®, Inc. , announced today that the first patient to use MammaPrint® as an enrollment biomarker for the DEBRA Trial is to be enrolled.

Key Points: 
  • Agendia®, Inc. , announced today that the first patient to use MammaPrint® as an enrollment biomarker for the DEBRA Trial is to be enrolled.
  • The Phase III NRG Oncology De-Escalation of Breast Radiation (DEBRA) Trial ( NCT04852887 ) is a clinical study looking at safely reducing the use of breast radiation after lumpectomy for people with low-risk, early-stage breast cancer.
  • “With the first patient of this study being enrolled using MammaPrint, we look forward to participating in the development of a new path towards more precise, proactive treatment planning for early-stage breast cancer.”
    To learn more about the DEBRA Trial and enrollment criteria, visit www.nrgoncology.org/DEBRA-Trial .
  • For more information about Agendia, visit www.agendia.com and follow Agendia on Facebook , Twitter , YouTube , and LinkedIn .

Nucleic Acid Isolation and Purification (Genomic DNA, Plasmid DNA, mRNA) Market Research - Global Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 3, 2024

In 2022, the kits segment accounted for the largest share of the global nucleic acid isolation and purification market.

Key Points: 
  • In 2022, the kits segment accounted for the largest share of the global nucleic acid isolation and purification market.
  • In 2022, the kits segment accounted for the largest share of the global nucleic acid isolation and purification market.
  • Based on type, the global nucleic acid isolation and purification market is segmented into plasmid DNA, total RNA, circulating nucleic acid, genomic DNA, messenger RNA, microRNA, and other nucleic acid isolation and purification types.
  • In 2022, the plasmid DNA isolation and purification segment dominated the global nucleic acid isolation and purification market.

Almaden Genomics’ g.nome™ Further Enhances Single-Cell Analysis

Retrieved on: 
Wednesday, December 13, 2023

Almaden Genomics has incorporated an end-to-end solution into g.nome™ to process, analyze, and visualize single-cell RNAseq data.

Key Points: 
  • Almaden Genomics has incorporated an end-to-end solution into g.nome™ to process, analyze, and visualize single-cell RNAseq data.
  • A cloud-native platform designed for high-throughput sequencing data analysis, g.nome now includes features for alignment and quantification of gene expression per cell, Seurat clustering analysis, reference-based cell-type annotation, and built-in parallelization.
  • The g.nome platform also provides a powerful, yet flexible system for single cell analysis with a workflow builder, quick and easy plug-n-play workflows, and interactive visualizations.
  • Single-cell analysis was added to g.nome earlier this year, enabling understanding of cellular diversity and disease mechanisms on a much more granular level.

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS

Retrieved on: 
Friday, December 8, 2023

"A large unmet need in the treatment of breast cancer is that the majority of breast cancers are immune quiescent; resulting in minimal response to immunotherapies.

Key Points: 
  • "A large unmet need in the treatment of breast cancer is that the majority of breast cancers are immune quiescent; resulting in minimal response to immunotherapies.
  • A functional pathway enrichment analysis was conducted and confirmed positive changes in T-cell activation, lymphocyte activation and inflammatory response.
  • Over 95% of treatment-emergent adverse events (TEAEs) were low grade 1 or 2 primarily localized pain, fatigue, and nausea.
  • We see the potential opportunity for our technology and drug products in both the metastatic and presurgical settings for many types of cancers."

Lexogen Unveils LUTHOR High-Definition Single Cell 3' mRNA-Seq Kit, Revolutionizing Single-Cell RNA Sequencing

Retrieved on: 
Tuesday, November 14, 2023

LUTHOR HD is a cutting-edge protocol that opens the doors to the world of High-Definition Single-Cell RNA sequencing.

Key Points: 
  • LUTHOR HD is a cutting-edge protocol that opens the doors to the world of High-Definition Single-Cell RNA sequencing.
  • The key to LUTHOR HD's exceptional sensitivity lies in its innovative THOR (T7 High-resolution Original RNA amplification) technology.
  • Lexogen's LUTHOR HD revolutionizes single-cell RNA sequencing, providing researchers with an unprecedented level of sensitivity, simplicity, and cost-efficiency.
  • Together with this product launch, Lexogen is proud to further characterize High-Definition Single-Cell RNA sequencing in November's edition of Nature Methods.

Lexogen Unveils LUTHOR High-Definition Single Cell 3' mRNA-Seq Kit, Revolutionizing Single-Cell RNA Sequencing

Retrieved on: 
Tuesday, November 14, 2023

LUTHOR HD is a cutting-edge protocol that opens the doors to the world of High-Definition Single-Cell RNA sequencing.

Key Points: 
  • LUTHOR HD is a cutting-edge protocol that opens the doors to the world of High-Definition Single-Cell RNA sequencing.
  • The key to LUTHOR HD's exceptional sensitivity lies in its innovative THOR (T7 High-resolution Original RNA amplification) technology.
  • Lexogen's LUTHOR HD revolutionizes single-cell RNA sequencing, providing researchers with an unprecedented level of sensitivity, simplicity, and cost-efficiency.
  • Together with this product launch, Lexogen is proud to further characterize High-Definition Single-Cell RNA sequencing in November's edition of Nature Methods.

MedGenome achieves 10x Genomics Certified Service provider qualification for single cell sequencing

Retrieved on: 
Tuesday, November 7, 2023

FOSTER CITY, Calif., Nov. 7, 2023 /PRNewswire/ -- MedGenome , a global precision medicine company specializing in omics solutions, announced today that it has achieved the 10x Genomics Certified Service Provider qualification for its single cell offering.

Key Points: 
  • FOSTER CITY, Calif., Nov. 7, 2023 /PRNewswire/ -- MedGenome , a global precision medicine company specializing in omics solutions, announced today that it has achieved the 10x Genomics Certified Service Provider qualification for its single cell offering.
  • Combining MedGenome's expertise in single cell data analysis promises to deliver groundbreaking insights into complex and rare diseases.
  • The 10x Genomics certification highlights MedGenome's expertise in offering single-cell sequencing tools to help researchers accelerate their genomic studies.
  • MedGenome is positioned as the top genomics research service provider in the San Francisco Bay Area.